Indole S1P Receptor Antagonists for Glaucoma and Dry Eye
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fungal infections, allergic diseases, and immune disorders lack effective sphingosine derivatives that can regulate sphingolipid functions and interact with sphingosine-1-phosphate receptors, limiting therapeutic options for conditions like glaucoma, dry eye, angiogenesis disorders, cardiovascular diseases, and pulmonary diseases.
Innovation Solution
Development of derivatives or analogues of sphingosine with specific structures that act as agonists or antagonists for sphingosine-1-phosphate receptors, capable of regulating sphingolipid functions, which are synthesized through various chemical schemes and tested for their biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional treatments for fungal infections, allergic diseases, and immune disorders are used, then existing therapeutic options are limited, but developing new sphingosine derivatives with specific receptor activity requires complex chemical synthesis and extensive testing
Solution Approach 1:
The patent modifies the chemical structure of sphingosine derivatives by changing parameters such as substituting hydroxyl groups with protective groups (e.g., acetyl, benzyl, methoxymethyl), adjusting the indole ring substituents, and modifying the side chain length and saturation. These parameter changes create a series of compounds with different biological activities, enabling the development of selective S1P receptor agonists and antagonists for various therapeutic applications.
Solution Approach 2:
The patent divides the sphingosine molecule into distinct functional segments: the sphingosine backbone, the indole ring system with specific substituents (R1-R6), and the side chain (A1-A2). By independently modifying each segment, the invention can create specific receptor agonists or antagonists. For example, changing the indole substituents (R1-R6) while keeping the sphingosine backbone intact allows for selective receptor binding without affecting the basic sphingolipid structure.
2Adaptability or versatility
If sphingosine derivatives are synthesized through multiple chemical schemes, then diverse biological activities can be achieved, but the synthesis process becomes time-consuming and complex
Solution Approach 1:
The patent employs preliminary protective group strategies where hydroxyl groups are converted to protective groups (acetyl, benzyl, methoxymethyl) before certain synthesis steps. This preliminary action prevents unwanted reactions during intermediate steps and allows for more efficient final deprotection. For example, converting hydroxyl groups to acetyl groups beforehand prevents them from reacting with reagents that would otherwise modify the sphingosine backbone, thereby simplifying the overall synthesis pathway.
Solution Approach 2:
The patent creates a universal synthesis framework where a core sphingosine derivative can be modified through standardized reactions to produce multiple biologically active compounds. The same synthetic scheme can generate different receptor agonists or antagonists by simply changing the indole substituents (R1-R6) or side chain parameters, eliminating the need for entirely different synthesis pathways for each biological application.
3Reliability
If multiple sphingosine derivatives are tested for biological activity, then effective compounds can be identified, but the testing process becomes extensive and resource-intensive
Solution Approach 1:
The patent applies local quality by focusing modification on specific local regions of the sphingosine molecule that are critical for receptor interaction. By concentrating structural changes in the indole ring substituents (R1-R6) and side chain regions while maintaining the core sphingosine structure, the invention efficiently identifies active compounds. This localized modification strategy allows for targeted biological activity testing rather than randomly testing all possible sphingosine derivatives.
Data Source
AI summary
The present invention provides novel compounds having the following general formula Iwherein: A, B, X, Y, R1, R2, R3, R4, n, o and p are as defined in the specification. Such compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions or diseases and wound healing.